A Peptide From Egg Whites Lowered Blood Pressure by Up to 40 mmHg in Hypertensive Rats

Male spontaneously hypertensive rats (16–17 weeks old) were given oral IRW at either a low dose (3 mg/kg body weight) or high dose (15 mg/kg) daily for 18 days, with untreated SHRs as controls. Blood pressure and heart rate were monitored continuously via implanted telemetry devices. After the treatment period, animals were sacrificed for vascular function studies, and inflammatory markers and tissue fibrosis were measured.

Finding food-derived peptides that can lower blood pressure could lead to functional foods or supplements for managing hypertension with fewer side effects than pharmaceutical drugs. This study is notable because IRW works through multiple mechanisms simultaneously — ACE inhibition, nitric oxide support, and anti-inflammation — which mirrors the complex pathology of hypertension better than single-target drugs.

Food-derived bioactive peptides are a growing area of nutraceutical research. IRW is part of a broader class of ACE-inhibitory peptides found in milk, fish, soy, and eggs. While most remain in preclinical stages, the idea that common food proteins contain fragments that could help manage blood pressure is driving interest in functional food development as a complement to traditional pharmaceuticals.

This is an animal study using a specific rat model of hypertension (SHR), so results may not translate directly to humans. The study lasted only 18 days, so long-term effects and safety are unknown. Sample sizes per group were not specified in the abstract. The SHR model represents essential hypertension specifically and may not reflect other causes of high blood pressure. Oral bioavailability of the peptide in humans could differ significantly from rats.